The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It depends on how serious governments across the world want to ensure this never happens again. LFT’s leave unacceptable holes, PCR’s are too slow. The problem has not been resolved yet using these options therefore lockdowns remain the ultimate answer.
Again you have concurred with my point. This has the potential calibre of being of interest to the likes of Fuji but that takes time. It may ultimately appear in airports in a few years time alongside the drugs and explosive test machine. What it isn't is the high volume celebrity solution that has made some people very rich.
I think the quiet is a good sign. You only need shout if no one is listening. RNS states it is passing data ‘requested’ by partners combined with an updated time line and no further mention of taking the test to market ourselves. The conversion from lab to commercial product had to be at least end of June as per the advertised job description back in March. The partners mentioned have to be considered to be Malvern Panalytical and Pion and again as I’ve mentioned before,!the jury is out on whether GSK, Astra and Fuji are classed as partners as suggested on Paraytec’s website when considering what this small device was initially devised for in the first place prior to Covid hitting the world. No, I don’t think GSK and Astra would ever sell Covid tests but Fuji could easily meet a global scale if required. I have put out there the news article that they are working with at least the U.K. government to help create new innovative Covid tests at scale and make the U.K. a leader. The fact is Paraytec have worked with these giants using its Actipix.
It may well be the government would like the test but I do get a sense of others nipping at the heels. The quiet from the company suggests theres no razmataz surrounding the product to get the tie ups with the likes of BA. I've no doubt it will make it to market, but as a 'serious piece of kit' and not one that will become a 'household name'.
The government has been quite two faced so far - wanting the best but buying from China...
I wouldn’t worry about seconds. It’s a 2 min Antigen test targeting the commercial market. Ours is also 2 mins, but we also can tackle the matrix/pool testing which for example, a family of 4 would require one test 2 mins v 4 x 2 min tests and 4 x costs..
Example. - 1 £25 @ 2 mins v 4 x £25 @ 8 mins.
Jury is out regarding its accuracy scope after reading the small print.
I’m remembering the U.K. Government consultation regarding putting tests through more robust testing themselves as 70% of rapid kits don’t do what they say they do and also most sensitivity and specificity is affected in real world conditions.
You have sort of tuned into my point - whilst this is a better test and will stand the test of time it may be that it no longer offers the quick solution commercially if there are others that can on the face of it beat the time and satisfy the lesser requirements demanded by the commercial sector.
The Paraytec test will undoubtedly do well in the medical device space but the volume market may be too competitive ultimately. We will see.
Rocky500, worth reading the small print in this 25 second - 2 min test
It is possible for a person to test too early or too late during COVID-19 infection to make an accurate diagnosis using the Pelican COVID-19 Ultra-Rapid Mobile Test.
This test is to be performed only using saliva specimens collected by a healthcare professional for an individual aged 2 years or older. This test is authorized for use in these individuals regardless of whether they have symptoms or other epidemiological reasons to suspect a COVID-19 infection.
A negative test result for this test means that SARS- CoV-2 antigens were not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. The amount of antigen in a sample may decrease as the duration of illness increases.
https://docs.pelicandetect.com/EU%2B-%2BFact%2BSheet%2Bfor%2BHealthCare%2BProviders.pdf